Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients.
The aim of this study was to evaluate the effects of transdermal hormone replacement therapy on some biological cardiovascular risk factors, specifically the thromboxane B2 levels, plasma viscosity and the lipid profile. Furthermore, we investigated the Doppler flow modifications at the level of the uterine artery, the internal carotid, the ophthalmic and the bladder wall arteries, and we finally evaluated whether there were significant differences in the examined parameters between normal and overweight postmenopausal women. Forty-five postmenopausal women (mean age+/-standard deviation, 53.5+/-3.8 years) participated in the study and were divided into two groups (27 with a body mass index of < 25 kg/m2 and 18 with a body mass index of > 25 kg/m2). Patients were treated with a continous estradiol transdermal supplement and a 12-day course of medroxyprogesterone acetate every 2 months, and were studied at baseline and after 6 months (in the estrogen-only phase of the second cycle). Our results showed a beneficial effect of hormone substitution on plasma viscosity, thromboxane B2 levels and lipid profile after 6 months of therapy and significant improvements of Doppler flow parameters in the examined vessels. Furthermore, we observed a lower impact of the treatment in overweight women. In conclusion, obesity represents an additional cardiovascular risk condition and it can only partially be modified by the administration of hormone replacement therapy.
Persico
N
N
III Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy.
Mancini
F
F
Artini
P G
PG
Regnani
G
G
Volpe
A
A
de Aloysio
D
D
Battaglia
C
C
D000279:Administration, Cutaneous; D001809:Blood Viscosity; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000150:complications / Q000000981:diagnostic imaging* / Q000517:prevention & control; D004717:Endometrium / Q000000981:diagnostic imaging; D004958:Estradiol / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D017698:Postmenopause; D011673:Pulsatile Flow; D012307:Risk Factors; D013929:Thromboxane B2 / Q000097:blood; D014280:Triglycerides / Q000097:blood; D018615:Ultrasonography, Doppler, Color; D001743:Urinary Bladder / Q000000981:diagnostic imaging; D014655:Vascular Resistance
D008055:Lipids; D014280:Triglycerides; D004958:Estradiol; D013929:Thromboxane B2; D017258:Medroxyprogesterone Acetate